Amgen's Clinical Momentum Fails to Overcome Valuation and Base-Business Headwinds

What happened

Amgen and Vertex reportedly posted strong clinical trial results, with Amgen's obesity candidate MariTide continuing to generate positive data, but this news is already reflected in Amgen's premium valuation. The company's core business faces accelerating erosion from IRA price cuts on ENBREL and Otezla and biosimilar competition for Prolia and XGEVA, while Horizon-acquired assets show mixed performance. Filings reveal ENBREL net price declined 38% in Q3 2025, Otezla incurred a $1.2 billion impairment, and RANKL patents have expired, signaling structural pressures that will persist. Despite robust revenue growth driven by volume (13% in 2025), margin sustainability is uncertain as low-margin products replace high-margin legacy biologics. At ~$339 per share, Amgen trades at ~23.7x earnings and ~19.4x EV/EBITDA, leaving little room for execution missteps.

Implication

Investors should treat the latest clinical results as confirming the MariTide story but not adding incremental value at current levels, given the stock's rich multiple and well-flagged base-business deterioration. Near-term catalysts such as 2026 guidance, Part 2 Phase 2 MariTide data, and MARITIME enrollment progress will determine whether the premium is justified, but policy-driven price cuts and biosimilar erosion are certain and will compress margins. The balance sheet remains leveraged (net debt/EBITDA ~4.1x on FMP basis) and an unresolved IRS tax dispute could trigger cash payments substantially above accruals, further pressuring free cash flow and deleveraging plans. While the obesity opportunity is real, competition from Novo Nordisk and Eli Lilly is intense, and Medicare's refusal to cover weight-loss drugs limits near-term market access. A disciplined approach would avoid new positions above $340, use rallies toward $370 to reduce exposure, and consider adding only if shares retreat to the $295-$300 range with intact guidance.

Thesis delta

The thesis remains unchanged: Amgen's valuation already discounts sustained growth and obesity optionality, and the latest clinical news is incremental rather than transformative. The risk-reward continues to skew mildly negative over the next 6-18 months given certain policy and biosimilar headwinds versus a pipeline inflection that is still ahead. No change to the POTENTIAL SELL rating; conviction remains 3.5, with trim above $370 and attractive entry at $295.